%0 Journal Article
%T Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions
%A Jan M. Kitzen
%A Joseph V. Pergolizzi Jr.
%A Robert Taylor Jr.
%A Robert B. Raffa
%J Pharmacology & Pharmacy
%P 357-381
%@ 2157-9431
%D 2018
%I Scientific Research Publishing
%R 10.4236/pp.2018.99028
%X <span style=\"font-family:;\" \"=\"\">Two
selective phosphodiesterase-4 (PDE4) inhibitors¡ªviz., crisaborole (Eucrisa</span><sup><span><span style=\"font-family:verdana, Arial, Helvetica, sans-serif;font-size:14px;white-space:normal;\">&amp;reg;</span></span></sup><span style=\"font-family:;\" \"=\"\">,
Pfizer) and apremilast (Otezla</span><sup><span><span style=\"font-family:verdana, Arial, Helvetica, sans-serif;font-size:14px;white-space:normal;\">&amp;reg;</span></span></sup><span style=\"font-family:;\" \"=\"\">, Celgene)¡ªhave recently received approval by the United
States Food and Drug Administration for the treatment of related but different
dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis,
respectively). The purpose of this review is to summarize the underlying
biochemistry and pathophysiology associated with these dermatologic conditions,
review the chemistry, pharmacology and safety of each of these products, and
present preclinical and clinical evidence that may help explain why these two
PDE4 inhibitors offer new treatment options for these skin conditions.</span>
%K Crisaborole
%K Apremilast
%K Phosphodiesterase
%K PDE4
%K Inflammation
%K Cytokines
%K Interleukins
%K cAMP
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=87194